Adani Ports is well positioned to surpass revised guidance of FY24. Buy for target price of Rs 1600: Motilal Oswal

APSEZ is well on track to cross its revised cargo volume guidance of 400 MMT during FY24. It continues to gain market share while generating strong cash flows and maintaining its leverage position, with a net debt-to-EBITDA ratio of 2.5x as of Dec’23. We increase our volume estimates by 2-3% for FY24-26. Over FY24-26, we expect APSEZ to register 10% volume growth and a CAGR of 15%/16%/18% in revenue/EBITDA/PAT. With consistent outperformance in cargo volumes, we increase the target multiple to 17x EV/EBITDA (earlier 16x) and reiterate our BUY rating with a revised TP of INR1,600

Popular Vehicles (IPO) is a dealer for Maruti Suzuki and Tata Motors. Subscribe the issue for long term investment horizon: SBI Securities

In FY23, the company is the 7th largest Maruti Suzuki dealer under Arena and 9th under Nexa in India by volume. Ranked fourth in Tata Motors Commercial dealership sales during FY23, the company contributed 76.7% and 48.0% of sales in Kerala and Tamil Nadu as of 1HFY24

J Kumar Infraprojects is an Important Player to Ride on Indian Urban Infrastructure Landscape. Buy for target price of Rs 900 (25% upside): Axis Securities

We initiate coverage on J Kumar Infraprojects Limited (JKIL) with a BUY recommendation and a Target Price (TP) of Rs 800/share, implying an upside of 25% from the CMP. We believe JKIL, with its substantial order book, formidable market position, experienced management team, and sound financial standing, is poised to capitalize on the long-term structural changes in the infrastructure sector. These changes are being driven by the government’s emphasis on infrastructure development and the emergence of new opportunities in the construction space

CAN FIN Homes is poised for stronger performance. Buy for target price of Rs 1000 (25.8% upside): YES Securities

In the Investor Meetings hosted by us, Can Fin Homes have expressed significant confidence in delivering improved disbursements and loan growth and lower NPLs and credit cost over the coming quarters. Spread/NIM is expected to remain resilient in the near-term and glide towards the guided level of 2.5%/3.5% in the medium term

HDFC Bank’s merger related negatives are in price; valuation re-rating is expected. Buy for target price of Rs 1762 (22% upside): LKP

HDFC Bank is expected to overcome the merger overhangs gradually led by 1) healthy balance sheet growth, 2) much higher provision then regulatory requirement in the balance sheet, 3) best in class underwriting and risk management practices. Given these strengths we expect HDFC Bank to remain one of the best among all the lending businesses. Thus, we continue to maintain BUY rating (given historical lower valuation) on the bank with revised target price of ₹1,762

Nippon Life India Asset Management is at 32% discount to HDFC AMC. Buy for target price of Rs 610: PL

We initiate coverage on NAM with ‘BUY’ rating given (1) consistent equity outperformance translating to improved net flows and in-turn market share gains (2) focus on stronger investment process and risk management and (3) robust retail franchise as indicated by enhancing SIP AUM and healthy addition of unique investors plus folios over FY19 to 9MFY24

Top Specialty Chemical Stocks to buy for up to 40.3% upside potential by Deven Choksey Research

We recommend Rossari Biotech as the Company has strong demand from end customer segments, Fineotex Chemicals for its strong growth potential from capacity expansion and improved products mix towards finishing processes and Balaji Amines for the expansion plans and longterm growth prospects

Gopal Snacks Limited (IPO) is the largest manufacturer of Gathiya (31% market share) and has ~20 market share in total ethnic savouries market. Subscribe: SBI Sec

Gopal Snacks Ltd is a fast-moving consumer goods company based in India, offering a wide range of delicious snacks under the brand name ‘Gopal’. Established as a partnership firm in 1999 and incorporated as a company in 2009, the company currently operates in 10 States and 2 Union Territories as of 1HFY24

Top Stock Picks based on 3QFY24 Results by SBI Securities for Investment Horizon of 12 Months

We started this product on 16th June 2022 to offer our investors (A) An insight on the latest concluded quarterly result season, (B) Take basket approach towards best performing businesses and (C ) Ride on result driven capital appreciation story in equity market

Top 4 Pharma Stocks to buy now by HDFC Securities

Domestic formulations sector: secular growth stories The India Pharma Market (IPM) has maintained a steady ~10% CAGR from FY12 to FY23, despite various disruptions, driven mainly by volume expansion ranging between 5-10% during FY12-18, which subsequently tapered to 2-3% from FY19-23, primarily due to generic competition (FY22 growth was on a low base due to […]